{"schema_version":"secwatch.filing_event.v1","accession":"0001919246-26-000110","form_type":"8-K","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2026-08-13T11:00:34+00:00","discovered_at":"2026-08-13T11:05:00.607698+00:00","generated_at":"2026-08-13T11:05:29.710180+00:00","sec_items":["4.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pelthos Therapeutics restates Q1 2026 results due to convertible debt valuation error","bullets":["Non-reliance on Q1 2026 10-Q; restatement due to ASC 820 misapplication for Level 3 convertible debt fair value.","Restatement increases convertible debt fair value by $15.8M, accumulated deficit by $14.8M, reduces AOCI by $1.0M.","Non-cash expense up $14.8M; no impact on revenue, operating expenses, or cash position.","Material weakness in internal controls over Level 3 fair value measurements; remediation planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001919246-26-000110","json":"https://secwatch.observer/filing/0001919246-26-000110.json","markdown":"https://secwatch.observer/filing/0001919246-26-000110.md","text":"https://secwatch.observer/filing/0001919246-26-000110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/0001919246-26-000110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000191924626000110/pths-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:05:29.710180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}